[1] Rehermann B,Bertoletti A.Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections. Hepatology,2015,61(2):712-721.
[2] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):Ⅴ-ⅩⅩⅢ.
[3] 柴艳云,李建国,张新龙,等. 阿德福韦酯与恩替卡韦治疗HBeAg阳性慢性乙型肝炎患者临床疗效观察.实用肝脏病杂志,2014,17(3):307-308.
[4] Keating GM.Entecavir:a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease. Drugs,2011,71(18):2511-2529.
[5] 陆伟,张占卿,沈芳,等. 血清HBsAg和HBV DNA定量水平预测慢性乙型肝炎患者肝组织炎症活动度和纤维化程度的评价.实用肝脏病杂志,2016,19(1):20-24,25.
[6] Liaw YF,Sheen IS,Lee CM,et al.Tenofovir disoproxil fumarate (TDF),emtricitabine/TDF,and entecavir in patients with decompensated chronic hepatitis B liver disease.Hepatology,2011,53(1):62-72.
[7] Yuan Y,Iloeje UH,Hay J,Saab S.Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients.J Manag Care Pharm,2008,14(1):21-33.
[8] Papatheodoridis GV,Chan HL,Hansen BE,et al.Risk of hepatocellular carcinoma in chronic hepatitis B:Assessment and modification with current antiviral therapy. J Hepatol,2015,62(4):956-967. |